EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases

Agata Mostkowska iD, Guy Rousseau iD, Noël J-M Raynal iD

The FASEB Journal · 15.03.2024 · 38 (5)

DOI: 10.1096/fj.202302259rr ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 12.03.2024. Verfasst von Agata Mostkowska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Autoimmune Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds de recherche en Santé du Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off‐label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 115 autoimmune diseases across 17 medical specialties, sourced from over 1530 publications. Our work highlights the extent of its off‐label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune‐related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting cluster of differentiate 20 positive (CD20) B cells in 115 autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsAutoimmune DiseasesHumansRituximabDrug RepositioningOff-Label UseRare Diseases

Stichwörter der Autor:innen

autoimmune diseasesbiological therapybiosimilarsdrug repurposingimmunotherapymonoclonal antibodiesoff-label userituximab

Substanzen

RituximabBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Centre de recherche du CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada.

ORCID-Profile: Agata Mostkowska, Guy Rousseau, Noël J-M Raynal

Förderung

  • Fonds de recherche en Santé du Québec

Zitieren

APA

Mostkowska, A., Rousseau, G., & Raynal, N. J. (2024). Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases. The FASEB Journal, 38(5). https://doi.org/10.1096/fj.202302259rr

Vancouver

Mostkowska A, Rousseau G, Raynal NJ. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases. The FASEB Journal. 2024;38(5). doi:10.1096/fj.202302259rr

BibTeX
@article{Mostkowska2024,
  author = {Mostkowska, Agata and Rousseau, Guy and Raynal, Noël J-M},
  title = {Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {5},
  doi = {10.1096/fj.202302259rr}
}
Kostenlos starten →